Interview with Ulrich Eggert, Managing Director, Astellas Pharma Germany
Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the…
Address: Am Klopferspitz 19
82152 Planegg-Martinsried
Tel: +49. 89. 78 79 73 10
Web: http://www.chromotek.com/home/
Chromotek GmbH, a biotech spin-off from the LMu Munich founded in 2008, aims to establish Chromobodies®, (which are highly efficient functional binding reagents for a multitude of immuno-logical and biochemical applications), as superior substitutes for conventional antibodies in areas like proteome analysis, target screening/validation, cell sorting and live cell HCA. on the basis of its technology (patent pending). The team of 5 biologists around CEO Ulrich Rothbauer develops novel analytical and preparative solutions for the biomolecular research market. It has successfully launched the GFP-trap®, the best commercially available pull-down reagent for GFP and/or GFP fusion proteins.
Astellas has been present in the German market for almost two decades through Yamanouchi and Fujisawa. But since 2005 it gained a new identity thanks to the merger of the…
Cytonet is today Germany’s largest cell therapy enterprise. However, it went through many transformations since its spin-off from Roche Diagnostics in 2000. Could you briefly introduce the company to our…
The German Pharmaceutical Industry is not only known for its cutting-edge R&D and production base but also for having a high penetration of generics. In your opinion, what role do…
You have a wide experience in the pharmaceutical industry having worked for companies such as Amgen and Servier. What attracted you to Basilea? When I first considered moving to Basilea…
When we met Dr. Aleiotti in Italy, he said how important was Menarini´s acquisition of Berlin Chemie in the 1990s for the internationalization of the company in Eastern Europe and…
See our Cookie Privacy Policy Here
